Ribomic, Inc. (JP:4591)
:4591
Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥72.00 - ¥141.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥4.51B
Enterprise Value¥2.18B
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.64
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.67
Shares Outstanding54,332,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.30
Price to Sales (P/S)1880.02
P/FCF Ratio-3.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers financial risk and preserves strategic optionality. For an early-stage biotech that burns cash, having no interest-bearing liabilities lengthens runway flexibility, improves negotiating leverage with partners, and reduces short-to-medium-term solvency pressure.
Proprietary Aptamer PlatformOwning a proprietary aptamer platform focused on ophthalmology and rare diseases creates a durable scientific moat: platform-driven discovery can lower marginal R&D cost per asset, enable multiple program launches, and attract long-term collaboration agreements in high-unmet-need, high-barrier therapeutic niches.
Licensing And Partnership Revenue ModelA business model centered on licensing, collaborations, and milestone payments enables non-dilutive capital inflows and risk-sharing with larger pharma partners. Over time this model can monetize pre-commercial assets, reduce full development cost exposure, and create recurring partner-driven funding streams.
Bears Say
Minimal And Volatile RevenueExtremely low and inconsistent revenue undermines the firm's ability to self-fund R&D or operations. With commercialization traction minimal, the company remains dependent on sporadic partnership milestones and external financing, increasing execution risk and making multi‑period planning difficult.
Persistent Negative Operating & Free Cash FlowSustained operating and free cash flow deficits signal ongoing cash burn that exceeds internal resources. Even with some year-to-year improvement, continuous negative cash conversion implies recurring financing needs, potential dilution, and constrained ability to scale or pursue opportunistic investments over the next several quarters.
Eroding Equity And Large LossesMaterial decline in equity coupled with persistent operating and net losses weakens the balance sheet buffer and reduces financial resilience. Continued capital erosion narrows strategic options, raises the probability of dilutive financings, and limits ability to absorb clinical or development setbacks.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥72.00 and its highest was ¥141.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥4.51B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is May 19, 2026 which is in 25 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on Feb 12, 2026. The company reported -¥4.67 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.67.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 54,332,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥4.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Linical Co., Ltd.
―
CanBas Co., Ltd.
―
Takara Bio Inc.
―